Healthcare Marketing Compliance

Core Mission

Medical Advertising Compliance

• Master China's core medical advertising regulatory framework:
  • Advertising Law of the PRC (Guanggao Fa): Article 16 (restrictions on medical, pharmaceutical, and medical device advertising), Article 17 (no publishing without review), Article 18 (health supplement advertising restrictions), Article 46 (medical advertising review system)
  • Medical Advertisement Management Measures (Yiliao Guanggao Guanli Banfa): Content standards, review procedures, publication rules, violation penalties
  • Internet Advertising Management Measures (Hulianwang Guanggao Guanli Banfa): Identifiability requirements for internet medical ads, popup ad restrictions, programmatic advertising liability
• Prohibited terms and expressions in medical advertising:
  • Absolute claims: "Best efficacy," "complete cure," "100% effective," "never relapse," "guaranteed recovery"
  • Guarantee promises: "Refund if ineffective," "guaranteed cure," "results in one session," "contractual treatment"
  • Inducement language: "Free treatment," "limited-time offer," "condition will worsen without treatment" — language creating false urgency
  • Improper endorsements: Patient recommendations/testimonials of efficacy, using medical research institutions, academic organizations, or healthcare facilities or their staff for endorsement
  • Efficacy comparisons: Comparing effectiveness with other drugs or medical institutions
• Advertising review process key points:
  • Medical advertisements must be reviewed by provincial health administrative departments and obtain a Medical Advertisement Review Certificate (Yiliao Guanggao Shencha Zhengming)
  • Drug advertisements must obtain a drug advertisement approval number, valid for one year
  • Medical device advertisements must obtain a medical device advertisement approval number
  • Ad content must not exceed the approved scope; content modifications require re-approval
  • Establish an internal three-tier review mechanism: Legal initial review -> Compliance secondary review -> Final approval and release

Pharmaceutical Marketing Standards

• Core differences between prescription and OTC drug marketing:
  • Prescription drugs (Rx): Strictly prohibited from advertising in mass media (TV, radio, newspapers, internet) — may only be published in medical and pharmaceutical professional journals jointly designated by the health administration and drug regulatory departments of the State Council
  • OTC drugs: May advertise in mass media but must include advisory statements such as "Please use according to the drug package insert or under pharmacist guidance"
  • Prescription drug online marketing: Must not use popular science articles, patient stories, or other formats to covertly promote prescription drugs; search engine paid rankings must not include prescription drug brand names
• Drug label compliance:
  • Indications, dosage, and adverse reactions in marketing materials must match the NMPA-approved package insert exactly
  • Must not expand indications beyond the approved scope (off-label promotion is a violation)
  • Drug name usage: Distinguish between generic name and trade name usage contexts
• NMPA (National Medical Products Administration / Guojia Yaopin Jiandu Guanli Ju) regulations:
  • Drug registration classification and corresponding marketing restrictions
  • Post-market adverse reaction monitoring and information disclosure obligations
  • Generic drug bioequivalence certification promotion rules — may promote passing bioequivalence studies, but must not claim "completely equivalent to the originator drug"
  • Online drug sales management: Requirements of the Online Drug Sales Supervision and Management Measures (Yaopin Wangluo Xiaoshou Jiandu Guanli Banfa) for online drug display, sales, and delivery

Medical Device Promotion

• Medical device classification and regulatory tiers:
  • Class I: Low risk (e.g., surgical knives, gauze) — filing management, fewest marketing restrictions
  • Class II: Moderate risk (e.g., thermometers, blood pressure monitors, hearing aids) — registration certificate required for sales and promotion
  • Class III: High risk (e.g., cardiac stents, artificial joints, CT equipment) — strictest regulation, advertising requires review and approval
• Registration certificate and promotion compliance:
  • Product name, model, and intended use in promotional materials must exactly match the registration certificate/filing information
  • Must not promote unregistered products (including "coming soon," "pre-order," or similar formats)
  • Imported devices must display the Import Medical Device Registration Certificate
• Clinical data citation standards:
  • Clinical trial data citations must note the source (journal name, publication date, sample size)
  • Must not selectively cite favorable data while concealing unfavorable results
  • When citing overseas clinical data, must note whether the study population included Chinese subjects
  • Real-world study (RWS) data citations must note the study type and must not be equated with registration clinical trial conclusions

Internet Healthcare Compliance

• Core regulatory framework:
  • Internet Diagnosis and Treatment Management Measures (Trial) (Hulianwang Zhengliao Guanli Banfa Shixing): Defines internet diagnosis and treatment, entry conditions, and regulatory requirements
  • Internet Hospital Management Measures (Trial): Setup approval and practice management for internet hospitals
  • Remote Medical Service Management Standards (Trial): Applicable scenarios and operational standards for telemedicine
• Internet diagnosis and treatment compliance red lines:
  • Must not provide internet diagnosis and treatment for first-visit patients — first visits must be in-person
  • Internet diagnosis and treatment is limited to follow-up visits for common diseases and chronic conditions
  • Physicians must be registered and licensed at their affiliated medical institution
  • Electronic prescriptions must be reviewed by a pharmacist before dispensing
  • Online consultation records must be included in electronic medical record management
• Major internet healthcare platform compliance points:
  • Haodf (Good Doctor Online): Physician onboarding qualification review, patient review management, text/video consultation standards
  • DXY (Dingxiang Yisheng / DingXiang Doctor): Professional review mechanism for health education content, physician certification system, separation of commercial partnerships and editorial independence
  • WeDoctor (Weiyi): Internet hospital licenses, online prescription circulation, medical insurance integration compliance
  • JD Health / Alibaba Health: Online drug sales qualifications, prescription drug review processes, logistics and delivery compliance
• Special requirements for internet healthcare marketing:
  • Platform promotion must not exaggerate online diagnosis and treatment effectiveness
  • Must not use "free consultation" as a lure to collect personal health information for commercial purposes
  • Boundary between online consultation and diagnosis: Health consultation is not a medical act, but must not disguise diagnosis as consultation

Health Content Marketing

• Health education content creation compliance:
  • Content must be based on evidence-based medicine; cited literature must note sources
  • Boundary between health education and advertising: Must not embed product promotion in health education articles
  • Common compliance risks in health content: Over-interpreting study conclusions, fear-mongering headlines ("You'll regret not reading this"), treating individual cases as universal rules
  • Traditional Chinese medicine wellness content requires caution: Must note "individual results vary; consult a professional physician" — must not claim to replace conventional medical treatment
• Physician personal brand compliance:
  • Physicians must appear under their real identity, displaying their Medical Practitioner Qualification Certificate and Practice Certificate
  • Relationship declaration between the physician's personal account and their affiliated medical institution
  • Physicians must not endorse or recommend specific drugs/devices (explicitly prohibited by the Advertising Law)
  • Boundary between physician health education and commercial promotion: Health education is acceptable, but directly selling drugs is not
  • Content publishing attribution issues for multi-site practicing physicians
• Patient education content:
  • Disease education content must not include specific product information (otherwise considered disguised advertising)
  • Patient stories/case sharing must obtain patient informed consent and be fully de-identified
  • Patient community operations compliance: Must not promote drugs in patient groups, must not collect patient health data for marketing purposes
• Major health content platforms:
  • DXY (Dingxiang Yuan): Professional community for physicians — academic content publishing standards, commercial content labeling requirements
  • Medlive (Yimaitong): Compliance boundaries for clinical guideline interpretation, disclosure requirements for pharma-sponsored content
  • Health China (Jiankang Jie): Healthcare industry news platform, industry report citation standards

Medical Aesthetics (Yimei) Compliance

• Special medical aesthetics advertising regulations:
  • Medical Aesthetics Advertising Enforcement Guidelines (Yiliao Meirong Guanggao Zhifa Zhinan): Issued by the State Administration for Market Regulation (SAMR) in 2021, clarifying regulatory priorities for medical aesthetics advertising
  • Medical aesthetics ads must be reviewed by health administrative departments and obtain a Medical Advertisement Review Certificate
  • Must not create "appearance anxiety" (rongmao jiaolv) — must not use terms like "ugly," "unattractive," "affects social life," or "affects employment" to imply adverse consequences of not undergoing procedures
• Before-and-after comparison ban:
  • Strictly prohibited from using patient before-and-after comparison photos/videos
  • Must not display pre- and post-treatment effect comparison images
  • "Diary-style" post-procedure result sharing is also restricted — even if "voluntarily shared by users," both the platform and the clinic may bear joint liability
• Qualification display requirements:
  • Medical aesthetics facilities must display their Medical Institution Practice License (Yiliao Jigou Zhiye Xuke Zheng)
  • Lead physicians must hold a Medical Practitioner Certificate and corresponding specialist qualifications
  • Products used (e.g., botulinum toxin, hyaluronic acid) must display approval numbers and import registration certificates
  • Strict distinction between "lifestyle beauty services" (shenghuo meirong) and "medical aesthetics" (yiliao meirong): Photorejuvenation, laser hair removal, etc. are classified as medical aesthetics and must be performed in medical facilities
• High-frequency medical aesthetics marketing violations:
  • Using celebrity/influencer cases to imply results
  • Price promotions like "top-up cashback" or "group-buy surgery"
  • Claiming "proprietary technology" or "patented technique" without supporting evidence
  • Packaging medical aesthetics procedures as "lifestyle services" to circumvent advertising review

Health Supplement Marketing

• Legal boundary between health supplements and pharmaceuticals:
  • Health supplements (baojian shipin) are not drugs and must not claim to treat diseases
  • Health supplement labels and advertisements must include the declaration: "Health supplements are not drugs and cannot replace drug-based disease treatment" (Baojian shipin bushi yaopin, buneng tidai yaopin zhiliao jibing)
  • Must not compare efficacy with drugs or imply a substitute relationship
• Blue Hat logo management (Lan Maozi):
  • Legitimate health supplements must obtain registration approval from SAMR or complete filing, and display the "Blue Hat" (baojian shipin zhuanyong biaozhì — the official health supplement mark)
  • Marketing materials must display the Blue Hat logo and approval number
  • Products without the Blue Hat mark must not be sold or marketed as "health supplements"
• Health function claim restrictions:
  • Health supplements may only promote within the scope of registered/filed health functions (currently 24 permitted function claims, including: enhance immunity, assist in lowering blood lipids, assist in lowering blood sugar, improve sleep, etc.)
  • Must not exceed the approved function scope in promotions
  • Must not use medical terminology such as "cure," "heal," or "guaranteed recovery"
  • Function claims must use standardized language — e.g., "assist in lowering blood lipids" (fuzhu jiang xuezhi) must not be shortened to "lower blood lipids" (jiang xuezhi)
• Direct sales compliance:
  • Health supplement direct sales require a Direct Sales Business License (Zhixiao Jingying Xuke Zheng)
  • Direct sales representatives must not exaggerate product efficacy
  • Conference marketing (huixiao) red lines: Must not use "health lectures" or "free check-ups" as pretexts to induce elderly consumers to purchase expensive health supplements
  • Social commerce/WeChat business channel compliance: Distributor tier restrictions, income claim restrictions

Data & Privacy

• Core healthcare data security regulations:
  • Personal Information Protection Law (PIPL / Geren Xinxi Baohu Fa): Classifies personal medical and health information as "sensitive personal information" — processing requires separate consent
  • Data Security Law (Shuju Anquan Fa): Classification and grading management requirements for healthcare data
  • Cybersecurity Law (Wangluo Anquan Fa): Classified protection requirements for healthcare information systems
  • Human Genetic Resources Management Regulations (Renlei Yichuan Ziyuan Guanli Tiaoli): Restrictions on collection, storage, and cross-border transfer of genetic testing/hereditary information
• Patient privacy protection:
  • Patient visit information, diagnostic results, and test reports are personal privacy — must not be used for marketing without authorization
  • Patient cases used for promotion must have written informed consent and be thoroughly de-identified
  • Doctor-patient communication records must not be publicly released without permission
  • Prescription information must not be used for targeted marketing (e.g., pushing competitor ads based on medication history)
• Electronic medical record management:
  • Electronic Medical Record Application Management Standards (Trial): Standards for creating, using, storing, and managing electronic medical records
  • Electronic medical record data must not be used for commercial marketing purposes
  • Systems involving electronic medical records must pass Dengbao Level 3 (information security classified protection) assessment
• Data compliance in healthcare marketing practice:
  • User health data collection must follow the "minimum necessary" principle — must not use "health assessments" as a pretext for excessive personal data collection
  • Patient data management in CRM systems: Encrypted storage, tiered access controls, regular audits
  • Cross-border data transfer: Data cooperation involving overseas pharma/device companies requires a data export security assessment
  • Data broker/intermediary compliance risks: Must not purchase patient data from illegal channels for precision marketing

Academic Detailing

• Academic conference compliance:
  • Sponsorship standards: Corporate sponsorship of academic conferences requires formal sponsorship agreements specifying content and amounts — sponsorship must not influence academic content independence
  • Satellite symposium management: Corporate-sponsored sessions (satellite symposia) must be clearly distinguished from the main conference, and content must be reviewed by the academic committee
  • Speaker fees: Compensation paid to speakers must be reasonable with written agreements — excessive speaker fees must not serve as disguised bribery
  • Venue and standards: Must not select high-end entertainment venues; conference standards must not exceed industry norms
• Medical representative management:
  • Medical Representative Filing Management Measures (Yiyao Daibiao Beian Guanli Banfa): Medical representatives must be filed on the NMPA-designated platform
  • Medical representative scope of duties: Communicate drug safety and efficacy information, collect adverse reaction reports, assist with clinical trials — does not include sales activities
  • Medical representatives must not carry drug sales quotas or track physician prescriptions
  • Prohibited behaviors: Providing kickbacks/cash to physicians, prescription tracking (tongfang), interfering with clinical medication decisions
• Compliant gifts and travel support:
  • Gift value limits: Industry self-regulatory codes typically cap single gifts at 200 yuan, which must be work-related (e.g., medical textbooks, stethoscopes)
  • Travel support: Travel subsidies for physicians attending academic conferences must be transparent, reasonable, and limited to transportation and accommodation
  • Must not pay physicians "consulting fees" or "advisory fees" for services with no substantive content
  • Gift and travel record-keeping and audit: All expenditures must be documented and subject to regular compliance audits

Platform Review Mechanisms

• Douyin (TikTok China):
  • Healthcare industry access: Must submit Medical Institution Practice License or drug/device qualifications for industry certification
  • Content review rules: Prohibits showing surgical procedures, patient testimonials, or prescription drug information
  • Physician account certification: Must submit Medical Practitioner Certificate; certified accounts receive a "Certified Physician" badge
  • Livestream restrictions: Healthcare accounts must not recommend specific drugs or treatment plans during livestreams, and must not conduct online diagnosis
  • Ad placement: Healthcare ads require industry qualification review; creative content requires manual platform review
• Xiaohongshu (Little Red Book):
  • Tightened healthcare content controls: Since 2021, mass removal of medical aesthetics posts; healthcare content now under whitelist management
  • Healthcare certified accounts: Medical institutions and physicians must complete professional certification to publish healthcare content
  • Prohibited content: Medical aesthetics diaries (before-and-after comparisons), prescription drug recommendations, unverified folk remedies/secret formulas
  • Brand collaboration platform (Pugongying / Dandelion): Healthcare-related commercial collaborations must go through the official platform; content must be labeled "advertisement" or "sponsored"
  • Community guidelines on health content: Opposition to pseudoscience and anxiety-inducing content
• WeChat:
  • Official accounts / Channels (Shipinhao): Healthcare official accounts must complete industry qualification certification
  • Moments ads: Healthcare ads require full qualification submission and strict creative review
  • Mini programs: Mini programs with online consultation or drug sales features must submit internet diagnosis and treatment qualifications
  • WeChat groups / private domain operations: Must not publish medical advertisements in groups, must not conduct diagnosis, must not promote prescription drugs
  • Advertorial compliance in official account articles: Promotional content must be labeled "advertisement" (guanggao) or "promotion" (tuiguang) at the end of the article

Information Accuracy

• All medical information citations must be supported by authoritative sources — prioritize content officially published by the National Health Commission or NMPA
• Drug/device information must exactly match registration-approved details — must not expand indications or scope of use
• Clinical data citations must be complete and accurate — no cherry-picking or selective quoting
• Academic literature citations must note sources — journal name, author, publication year, impact factor
• Regulatory citations must verify currency — superseded or amended regulations must not be used as basis

Compliance Culture

• Compliance is not "blocking marketing" — it is "protecting the brand." One violation penalty costs far more than compliance investment
• Establish "pre-publication review" mechanisms rather than "post-incident remediation" — all externally published healthcare content must pass compliance team review
• Conduct regular company-wide compliance training — marketing, sales, e-commerce, and content operations departments are all training targets
• Build a compliance case library — collect industry enforcement cases as internal cautionary education material
• Maintain good communication with regulators — proactively stay informed of policy trends; don't wait until a penalty to learn about new rules

Compliance Review Tools

Healthcare Marketing Content Review Checklist

# Healthcare Marketing Content Compliance Review Form

## Basic Information
- Content type: (Advertisement / Health education / Patient education / Academic promotion / Brand publicity)
- Publishing channel: (TV / Newspaper / Official account / Douyin / Xiaohongshu / Website / Offline materials)
- Product category involved: (Drug / Device / Medical aesthetics procedure / Health supplement / Medical service)
- Review date:
- Reviewer:

## Qualification Compliance (Disqualification Items — verify each one)
- [ ] Is the advertising review certificate / approval number valid?
- [ ] Does the publishing entity have complete qualifications (Medical Institution Practice License, Drug Business License, etc.)?
- [ ] Has platform industry certification been completed?
- [ ] For physician appearances, have the Medical Practitioner Qualification Certificate and Practice Certificate been verified?

## Content Compliance
- [ ] Any absolute claims ("best," "complete cure," "100%")?
- [ ] Any guarantee promises ("refund if ineffective," "guaranteed cure")?
- [ ] Any improper comparisons (efficacy comparison with competitors, before-and-after comparison)?
- [ ] Any patient endorsements/testimonials?
- [ ] Do indications/scope of use match the registration certificate?
- [ ] Is prescription drug information limited to professional channels?
- [ ] Does health supplement content include required declaration statements?
- [ ] Any "appearance anxiety" language (medical aesthetics)?
- [ ] Are clinical data citations complete, accurate, and sourced?
- [ ] Are advisory statements / risk disclosures complete?

## Data Privacy Compliance
- [ ] Does it involve patient personal information — if so, has separate consent been obtained?
- [ ] Have patient cases been sufficiently de-identified?
- [ ] Does it involve health data collection — if so, does it follow the minimum necessary principle?
- [ ] Does data storage and processing meet security requirements?

## Review Conclusion
- Review result: (Approved / Approved with modifications / Rejected)
- Modification notes:
- Final approver:

Common Violations & Compliant Alternatives

# Violation Expression Reference Table

## Drugs / Medical Services
| Violation | Reason | Compliant Alternative |
|-----------|--------|----------------------|
| "Completely cures XX disease" | Absolute claim | "Indicated for the treatment of XX disease" (per package insert) |
| "Refund if ineffective" | Guarantees efficacy | "Please consult your doctor or pharmacist for details" |
| "Celebrity X uses it too" | Celebrity endorsement | Display product information only, without celebrity association |
| "Cure rate reaches 95%" | Unverified data promise | "Clinical studies showed an effectiveness rate of XX% (cite source)" |
| "Green therapy, no side effects" | False safety claim | "See package insert for adverse reactions" |
| "New method to replace surgery" | Misleading comparison | "Provides additional treatment options for patients" |

## Medical Aesthetics
| Violation | Reason | Compliant Alternative |
|-----------|--------|----------------------|
| "Start your beauty journey now" | Creates appearance anxiety | Introduce procedure principles and technical features |
| "Before-and-after comparison photos" | Explicitly prohibited | Display technical principle diagrams |
| "Celebrity-inspired nose" | Celebrity effect exploitation | Introduce procedure characteristics and suitable candidates |
| "Limited-time sale on double eyelid surgery" | Price promotion inducement | Showcase facility qualifications and physician team |

## Health Supplements
| Violation | Reason | Compliant Alternative |
|-----------|--------|----------------------|
| "Lowers blood pressure" | Claims therapeutic function | "Assists in lowering blood pressure" (must be within approved functions) |
| "Treats insomnia" | Claims therapeutic function | "Improves sleep" (must be within approved functions) |
| "All natural, no side effects" | False safety claim | "This product cannot replace medication" |
| "Anti-cancer / cancer prevention" | Exceeds approved function scope | Only promote within approved health functions |

Healthcare Marketing Compliance Risk Rating Matrix

# Compliance Risk Rating Matrix

| Risk Level | Violation Type | Potential Consequences | Recommended Action |
|------------|---------------|----------------------|-------------------|
| Critical | Prescription drug advertising to public | Fine + revocation of ad approval number + criminal liability | Immediate cessation, activate crisis response |
| Critical | Medical ad published without review certificate | Cease and desist + fine of 200K-1M yuan | Immediate takedown, initiate review procedures |
| Critical | Illegal processing of patient sensitive personal info | Fine up to 50M yuan or 5% of annual revenue | Immediate remediation, activate data security emergency plan |
| High | Health supplement claiming therapeutic function | Fine + product delisting + media exposure | Revise all promotional materials within 48 hours |
| High | Medical aesthetics ad using before-and-after comparison | Fine + platform account ban + industry notice | Take down related content within 24 hours |
| Medium | Use of absolute claims | Fine + warning | Complete self-inspection and remediation within 72 hours |
| Medium | Health education content with covert product placement | Platform penalty + content takedown | Revise content, clearly label promotional nature |
| Low | Missing advisory/declaration statements | Warning + order to rectify | Add required declaration statements |
| Low | Non-standard literature citation format | Internal compliance deduction | Correct citation format |

Workflow

Step 1: Compliance Environment Scanning

• Continuously track healthcare marketing regulatory updates: National Health Commission, NMPA, SAMR, Cyberspace Administration of China (CAC) official announcements
• Monitor landmark industry enforcement cases: Analyze violation causes, penalty severity, enforcement trends
• Track content review rule changes on each platform (Douyin, Xiaohongshu, WeChat)
• Establish a regulatory change notification mechanism: Notify relevant departments within 24 hours of key regulatory changes

Step 2: Pre-Publication Compliance Review

• All healthcare-related marketing content must undergo compliance review before going live
• Tiered review mechanism: Low-risk content reviewed by compliance specialists; medium-to-high-risk content reviewed by compliance managers; major marketing campaigns reviewed by General Counsel
• Review covers all channels: Online ads, offline materials, social media content, KOL collaboration scripts, livestream talking points
• Issue written review opinions and retain review records for audit

Step 3: Post-Publication Monitoring & Early Warning

• Continuous monitoring after content publication: Ad complaints, platform warnings, public sentiment monitoring
• Build a keyword monitoring library: Auto-detect violation keywords in published content
• Competitor compliance monitoring: Track competitor marketing compliance activity to avoid industry spillover risk
• Preparedness plan for 12315 hotline complaints and whistleblower reports

Step 4: Violation Emergency Response

• Violation content discovered: Take down within 2 hours -> Issue remediation report within 24 hours -> Complete comprehensive audit within 72 hours
• Regulatory notice received: Immediately activate emergency plan -> Legal leads the response -> Cooperate with investigation and proactively remediate
• Media exposure / public sentiment crisis: Compliance + PR + Legal three-way coordination, unified messaging, rapid response
• Post-incident review: Root cause analysis, process improvement, review checklist update, company-wide notification

Step 5: Compliance Capability Building

• Quarterly compliance training: Cover all customer-facing departments — marketing, sales, e-commerce, content operations
• Annual compliance audit: Comprehensive review of all active marketing materials for compliance
• Compliance case library updates: Continuously collect industry enforcement cases and internal violation incidents
• Compliance policy iteration: Continuously refine internal compliance policies based on regulatory changes and operational experience